Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

ation with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the return of development and commercialization rights to blinatumomab, the future development of blinatumomab and a new BiTE antibody binding to CD19, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, our plans regarding future presentations of clinical data, our expectations of timing for the publication of results from our research and development programs, our ability to draw down o
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... -- Calcivis, a medical devices company ... today announces that it has completed a first ... System. The Calcivis Caries Activity Imaging ... combination designed to transform the assessment and management ... unique, proprietary bioluminescence approach combined with a specialised ...
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... a professional and in-depth research report on the ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/26/2014)... In keeping with the holiday spirit, DNA ... Thanksgiving savings. The company is offering up a variety ... this holiday weekend as well as a photo contest ... Monday are right around the corner, and DNA Spectrum ... and those looking to explore their ancestry, health, and ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3
... CHAMPAIGN, Ill. Graphene, a single-atom-thick sheet of ... Whether graphene actually cuts it in industry, however, ... at the University of Illinois., Graphene consists of ... have predicted that the orientation of atoms along ...
... Ireland, Feb. 16 Copan Innovation Ltd., whose subsidiary ... and transport systems in the world, has named Bob ... in the Pacific Rim, as well as appointed Mr. ... Ltd. Bob Cooper, who brings a background of twenty ...
... aids in identifying connection between improved lipid profile and ... Using the VAP Cholesterol Test from Atherotech, ... an association between a rare gene mutation and heart ... help in the development of heart disease risk-lowering drugs ...
Cached Biology Technology:Scientists prove graphene's edge structure affects electronic properties 2Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 3VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 4
(Date:11/4/2014)... (Nov. 4, 2014) – A majority of Madagascar,s 101 ... could have serious consequences for the rainforests they call ... the positive impacts lemurs can have on rainforest tree ... disappearance could have on the region,s rich biodiversity. , ... fruits eaten by lemurs. Lemurs in turn disperse ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... thought that gene expression was modulated only by transcription factors. ... be regulated by the RISC complex (siRNA-mediated degradation via Dicer). ... is even more complex than we first imaginated... , ... for using a weapon or tool is finding it. And ...
... form of skin cancer, can be successfully treated in some ... work and why they are only effective in some patients ... articles in the January 17 issue of the Journal of ... of immune cells called killer T cells that can attack ...
... study, investigators in Japan found no association between a ... blood pressure, as reported in the March 1 issue ... , The researchers reported that they were not able ... the Kaposi's sarcoma virus, in the lungs of 22 ...
Cached Biology News:FDA Approves Human Hookworm Vaccine for Phase I Safety Trials 2FDA Approves Human Hookworm Vaccine for Phase I Safety Trials 3Association of herpesvirus with lung disorder questioned 2
Request Info...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
hnRNP U (H-94)...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
Biology Products: